Dutch biotech company Micreos' endolysin-based product Staphefeckt has shown promise in early case studies as a treatment for skin infections, exciting hopes of a new avenue of treatment in the battle against multi-drug antibiotic resistance.
Presenting the case studies at the EuroSciCon meeting in London, the company said its product Endolysin Staphefekt was able to...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
